Invirsa Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Series B1
- Latest Deal Amount
-
$1000K
- Investors
-
8
Invirsa General Information
Description
Developer of a pre-clinical therapeutic technology designed to reduce inflammation without compromising innate immunity. The company's platform develops a lead compound that is derived from a naturally occurring small molecule that modulates the activity of three parallel enzyme systems that are critical to innate immune response, enabling medical professionals to reduce inflammation and viral and possibly bacterial replication.
Contact Information
Website
www.invirsa.comCorporate Office
- 1275 Kinnear Road
- Columbus, OH 43212
- United States
Corporate Office
- 1275 Kinnear Road
- Columbus, OH 43212
- United States
Invirsa Timeline
Invirsa Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC (Series B1) | 14-Nov-2023 | $1000K | Completed | Pre-Clinical Trials | ||
| 7. Later Stage VC (Series B) | 01-Apr-2023 | Completed | Pre-Clinical Trials | |||
| 6. Accelerator/Incubator | 09-Oct-2020 | Completed | Startup | |||
| 5. Grant | 29-Sep-2020 | Completed | Pre-Clinical Trials | |||
| 4. Later Stage VC (Series A1) | 20-Dec-2019 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series A2) | 05-Oct-2018 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A2) | 28-Jul-2017 | $520K | $710K | Completed | Pre-Clinical Trials | |
| 1. Angel (individual) | 15-Jul-2016 | $190K | $190K | Completed | Startup |
Invirsa Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A-3 | ||||||||
| Series A-2 | 313,260 | $0.000010 | 8% | $2.45 | $2.45 | 1x | $2.45 | 11.7% |
| Series A-1 | 524,322 | $0.000010 | 8% | $3.43 | $3.43 | 1x | $3.43 | 19.58% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Invirsa Comparisons
Industry
Financing
Details
Invirsa Competitors (60)
One of Invirsa’s 60 competitors is Viriom, a Venture Capital-Backed company based in Rockville, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Viriom | Venture Capital-Backed | Rockville, MD | ||||
| Fedora Pharmaceuticals | Formerly Angel backed | Edmonton, Canada | ||||
| EnGeneIC | Venture Capital-Backed | Sydney, Australia | ||||
| Venatorx Pharmaceuticals | Venture Capital-Backed | Malvern, PA | ||||
| Jnana Therapeutics | Formerly VC-backed | Boston, MA |
Invirsa Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Invirsa Patents
Invirsa Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4226971-A1 | Methods for the use of 5'-adenosine diphosphate ribose (adpr) | Pending | 27-Mar-2018 | ||
| US-20190298752-A1 | Methods for the use of 5'-adenosine diphosphate ribose (adpr) | Active | 27-Mar-2018 | ||
| US-20210161936-A1 | Methods for the use of 5'-adenosine diphosphate ribose (adpr) | Active | 27-Mar-2018 | ||
| US-20230414647-A1 | Methods for the use of 5'-adenosine diphosphate ribose (adpr) | Active | 27-Mar-2018 | ||
| ES-2949441-T3 | Methods for the use of 5'-adenosine diphosphate ribose (adpr) | Active | 27-Mar-2018 | A61K31/7076 |
Invirsa Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Invirsa Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| JobsOhio Growth Capital | Venture Capital | Minority | ||
| Jumpstart Ventures | Venture Capital | Minority | ||
| Endless Frontier Labs | Accelerator/Incubator | Minority | ||
| Biomedical Advanced Research and Development Authority | Government | Minority | ||
| Public Health Emergency | Government |
Invirsa FAQs
-
When was Invirsa founded?
Invirsa was founded in 2014.
-
Where is Invirsa headquartered?
Invirsa is headquartered in Columbus, OH.
-
What is the size of Invirsa?
Invirsa has 10 total employees.
-
What industry is Invirsa in?
Invirsa’s primary industry is Drug Discovery.
-
Is Invirsa a private or public company?
Invirsa is a Private company.
-
What is the current valuation of Invirsa?
The current valuation of Invirsa is .
-
What is Invirsa’s current revenue?
The current revenue for Invirsa is .
-
How much funding has Invirsa raised over time?
Invirsa has raised $11.4M.
-
Who are Invirsa’s investors?
JobsOhio Growth Capital, Jumpstart Ventures, Endless Frontier Labs, Biomedical Advanced Research and Development Authority, and Public Health Emergency are 5 of 8 investors who have invested in Invirsa.
-
Who are Invirsa’s competitors?
Viriom, Fedora Pharmaceuticals, EnGeneIC, Venatorx Pharmaceuticals, and Jnana Therapeutics are some of the 60 competitors of Invirsa.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
